Paul M. Ridker, MD, MPH
Eugene Braunwald Professor of Medicine
Harvard Medical School
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Harry L. Leider, MD, MBA
Chief Medical Officer
Senior Vice President
Senior Fellow, Department of Health Policy & Outcomes
Thomas Jefferson University
Physicians CME: 1 credit
Pharmacist CPE: 1.0 contact hour (0.1 CEU) Medium
THIS PROGRAM WAS ORIGINALLY RELEASED AS A LIVE AUDIOCONFERENCE SERIES BEGINNING ON SEPTEMBER 8, 2008. IF YOU RECEIVED CME OR CPE CREDIT FOR THE AUDIOCONFERENCE, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE VERSION.
This is the second program in a 2-part series.
Treatment for atherosclerosis quickly escalates from the basic to the invasive, the economical to the cost prohibitive. Traditionally, it starts with lifestyle changes – diet, exercise, smoking cessation – usually includes the addition of pharmacologic therapy, and may lead to interventional surgery. Sometimes all three approaches are necessary, but this costly continuum of care can be managed at every step while disease progression is delayed or halted. Several clinical studies have shown that the progression of atherosclerosis can sometimes even be reversed by treatment to aggressive target goals using effective doses of statins and combination approaches. This online capture of a live audioconference explores in greater depth strategies for treating and managing atherosclerosis and controlling its costs in a managed care setting. Program Developer/Facilitator
. Target Audience
Managed Care Medical Directors, Pharmacy Directors, and other physicians and pharmacists interested in the management of atherosclerosis
Upon completion of this educational activity, the participant should be able to:
Describe new studies that support the aggressive treatment of LDL and inflammation.
Identify treatments that will effectively reduce the costs associated with atherosclerosis.
Develop ways to enhance physician and patient adherence to evidence-based guidelines and treatment.
It is the policy of NAMCP to ensure independence, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NAMCP prior to accreditation of the activity.
Dr. Ridker has received funding for clinical research from AstraZeneca, Merck, Novartis, and sanofi-aventis. He has also served as a consultant to AstraZeneca, Dade-Behring, Merck-Schering Plough, and Novartis. He is also listed as a co-inventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease.
Dr. Leider has no current financial relationships that present a conflict of interest. Formerly of XLHealth Inc., Dr. Leider will be providing examples and methodology collected by XLHealth Inc. within his presentation. XLHealth Inc. offers Medicare Health Plans and provides disease management and wellness support services to chronically ill patients and their physicians, as well as to health plan providers and government entities. Credit Statements
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of National Association of Managed Care Physicians (NAMCP) Inc. and Medical Communications Media, Incorporated. NAMCP is accredited by the ACCME to provide continuing medical education for physicians.
NAMCP designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacists: ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Program Number 221-999-08-100-H01-P has been assigned to this home-study program (initial release date 12-01-08). This program is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. The program is provided at no cost to participants. Statements of credit will be issued online upon completion of the program evaluation and the post-test with a score of 70% or higher. No partial credit will be given. Commercial Support Statements
This activity is supported by an educational grant from AstraZeneca.
Please turn off all pop-up blockers.
Click on the “start program” icon. This will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or update/correct existing registration information. When ready, click on the “continue to program” icon at the bottom of the screen. This will take you to a brief pre-program survey.
The next screen will permit you to check for or download the Flash player required to run this program.
Clicking “start the program” will allow you to begin the program presentation. This activity will require approximately 60 minutes to complete.
Upon completion of the program, click on the post-test button to access the post-test and program evaluation. This will bring you to a brief post-program survey.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE statement of credit. Two attempts are allowed.
©2008, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this program are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the National Association of Managed Care Physicians, ProCE, or AstraZeneca. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.